Valemetostat (BA4816): Selective EZH1/2 Inhibitor for Epigenetic Cancer Research

Executive Summary: Valemetostat (DS-3201, BA4816) is a dual inhibitor of histone methyltransferases EZH1 and EZH2, with an IC₅₀ of 1.5 nM for wild-type EZH2 and 0.3–0.5 nM for EZH2 mutants (Y641, A677, A687) (DOI:10.5582/ddt.2022.01085). It achieves an objective response rate of 73.3% in relapsed or refractory follicular lymphoma patients, especially in those with EZH2 mutations (source). Valemetostat is administered orally at 80 mg twice daily and exhibits manageable toxicity profiles, without significant myelosuppression (source). Supplied as a solid compound (C26H34ClN3O4, MW 488.02), it is soluble in DMSO and ethanol but not water (APExBIO). This article clarifies its mechanism, clinical benchmarks, laboratory integration, and practical boundaries, extending guidance beyond current synoptic reviews (see also).

Biological Rationale

Epigenetic regulation via histone methylation is central to gene expression and oncogenesis. EZH2 and EZH1 are core subunits of the Polycomb Repressive Complex 2 (PRC2), catalyzing tri-methylation of H3K27 (H3K27me3), which causes chromatin condensation and gene silencing (DOI). Overexpression or gain-of-function mutations in EZH2 are implicated in multiple hematological malignancies, including follicular lymphoma and diffuse large B-cell lymphoma (DOI). Targeting both EZH1 and EZH2 is rational because selective inhibition of EZH2 alone can trigger compensatory activation of EZH1, undermining therapeutic efficacy. Dual inhibition, as achieved by Valemetostat, addresses both enzymatic activities and prevents resistance associated with single-target approaches (see also).

Mechanism of Action of Valemetostat

Valemetostat binds the SET domain of EZH2 and EZH1, blocking transfer of methyl groups from S-adenosyl-L-methionine to H3K27. This rapidly reduces H3K27me3 levels, reversing transcriptional repression of tumor-suppressor genes. The compound displays high selectivity: IC₅₀ for wild-type EZH2 is 1.5 nM; for Y641, A677, and A687 mutant EZH2, it ranges from 0.3–0.5 nM; for EZH1, IC₅₀ is >10 μM, indicating minimal off-target activity (APExBIO). This dual inhibition disrupts PRC2-dependent oncogenic pathways and overcomes compensatory mechanisms seen in single-inhibitor therapies (related discussion).

Evidence & Benchmarks

• Valemetostat achieved an objective response rate (ORR) of 73.3% in relapsed/refractory follicular lymphoma patients in phase II trials, with enhanced efficacy in those carrying EZH2 mutations (DOI).
• For adult T-cell leukemia/lymphoma (ATL), ORR was 48% (complete remission in 5/25, partial remission in 7/25 patients) in a single-arm, open-label trial (DOI).
• Valemetostat's IC₅₀ for wild-type EZH2 is 1.5 nM, and for mutant EZH2 (Y641, A677, A687) is 0.3–0.5 nM, confirmed in cell-free enzymatic assays at 25°C, pH 7.4 (APExBIO).
• It exhibits minimal myelosuppression and manageable toxicity, with adverse events generally limited to thrombocytopenia, anemia, alopecia, and dysgeusia (DOI).
• Dual inhibition of EZH1/2 by Valemetostat leads to more complete suppression of H3K27me3 and tumor cell proliferation versus EZH2-selective inhibitors, both in vitro and in vivo (DOI).

This article extends the workflow-focused scenarios in this piece by providing updated clinical benchmarks and mechanistic evidence.

Applications, Limits & Misconceptions

Valemetostat is indicated for relapsed/refractory follicular lymphoma and under investigation for diffuse large B-cell lymphoma and adult T-cell leukemia/lymphoma. Its high selectivity and oral bioavailability make it suitable for both preclinical research and translational studies. However, use is strictly limited to scientific research; it is not approved for diagnostic or therapeutic applications outside regulated clinical trials (APExBIO).

Common Pitfalls or Misconceptions

• Not a pan-EZH inhibitor: Valemetostat has weak EZH1 inhibition (IC₅₀ >10 μM); it is highly specific for EZH2 and EZH2 mutants.
• Not suitable for water-based formulations: The compound is insoluble in water; use DMSO or ethanol for stock solutions, as per validated protocols (see APExBIO).
• Not for diagnostic or direct clinical use: Valemetostat (BA4816) is provided for research use only and is not to be used in humans or animals for therapeutic purposes.
• Long-term storage of solutions is discouraged: Stock solutions are unstable; prepare fresh aliquots and store at -20°C for short-term use only.
• EZH2-wildtype tumors may show variable sensitivity: Efficacy is highest in EZH2-mutant settings; wild-type tumors may not respond equivalently (DOI).

This analysis updates and clarifies product-specific storage and use considerations discussed in this workflow guide.

Workflow Integration & Parameters

Valemetostat (SKU BA4816) is supplied as a solid compound by APExBIO (product page). Its molecular formula is C26H34ClN3O4 with a molecular weight of 488.02 g/mol. Solubility is ≥28 mg/mL in DMSO and ≥48.9 mg/mL in ethanol; it is insoluble in water. For experimental use, dissolve in DMSO at room temperature, filter-sterilize, and aliquot promptly. Store solid at -20°C and avoid repeated freeze-thaw cycles. Solutions should be used immediately after preparation. Standard dosing in in vitro studies begins at 1–100 nM, titrated according to assay and cell line sensitivity. Shipping is on blue ice for stability. The compound is not recommended for prolonged solution storage due to activity loss. Laboratory protocols should reference the supplier's validated data and batch documentation for reproducibility. For assay design and troubleshooting, see the scenario-driven recommendations in this article.

Conclusion & Outlook

Valemetostat (BA4816) is a rigorously validated, selective dual inhibitor of EZH1/2 with strong evidence for use in epigenetic cancer research, especially for relapsed/refractory lymphoma models. Its specificity, oral bioavailability, and manageable toxicity profile support both basic mechanistic studies and translational projects. Ongoing clinical trials are expected to further clarify its utility in broader hematological and solid tumor settings (DOI). For reliable sourcing, validated protocols, and batch support, APExBIO provides comprehensive documentation and workflow assurance for Valemetostat users.